Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03305809 | A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) | PHASE2 | COMPLETED | 344 | — | — | Nov 9, 2017 | Jul 10, 2020 | Jul 23, 2021 | 77 | United States, Canada +1 |
The CDR-CCB tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning which includes tests of attention (simple and choice reaction time, digit vigilance), working memory (spatial and numeric) and episodic memory (word recognition, picture recognition). Continuity of attention measures speed and accuracy and is calculated from 3 attentional tasks on the CDR computerized battery tests. For continuity of attention, the score range is -999 to 35. A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline. Data presented are model-based bayesian posterior mean response rates with 95% credible interval.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received placebo administered orally once a day (QD). |
| 10 milligram (mg) LY3154207 | EXPERIMENTAL | Participants received 10 mg LY3154207 administered orally QD. |
| 30 mg LY3154207 | EXPERIMENTAL | Participants received 30 mg LY3154207 administered orally QD. |
| 75 mg LY3154207 | EXPERIMENTAL | Participants received 75 mg LY3154207 administered orally QD. |
| Name | Type | Description |
|---|---|---|
| LY3154207 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
Inclusion Criteria: * Have dementia as defined by a decline in cognitive function, which in the opinion of the investigator has resulted in functional impairment. * Meet diagnostic criteria for PD per MDS criteria or DLB per 4th Consensus Report of the DLB Consortium. * Have a score on the MoCA of ...